IFLScience on MSN10d
FDA Breakthrough Therapy Designation Granted For Promising Rectal Cancer Drug
T he US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to a cancer drug called dostarlimab ...
Cure Today12d
FDA Grants Jemperli Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite ...
Cure Today10d
FDA Grants Breakthrough Therapy Designation to Trodelvy for Small Cell Lung Cancer
The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application
Following news that the U.S. Food and Drug Administration approved its New Drug Application for avutometinib in combination ...
Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment
Precigen submits BLA for PRGN-2012 gene therapy targeting RRP, a rare and life-threatening condition with no cure.
Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...
New Atlas13d
"100% successful" cancer drug gets landmark FDA approval
Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration ...
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.
Business Insider14d
Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non ...